ADVERTISEMENT

COVID in India: Remdesivir Exports Halted to Meet Domestic Demand

Published
Coronavirus
2 min read
COVID in India: Remdesivir Exports Halted to Meet Domestic Demand

In the wake of the recent surge in Covid-19 cases, India on Sunday, 11 April, prohibited the exports of remdesivir injections and active pharmaceutical ingredients (API) till the situation improves.

The decision was taken considering a sudden spike in demand for remdesivir, which is used in treatment of Covid-19 patients, a Health and Family Welfare Ministry statement said.

Noting India has 11.08 lakh active Covid cases as on Sunday, 11 April, amid an increasing trend, the Ministry said: "There is a potential of further increase in demand of injection remdesivir and remdesivir active pharmaceutical ingredients (API) in the coming days."

“In light of the above increasing Covid cases, Government of India has prohibited the exports of injection remdesivir and remdesivir active pharmaceutical ingredients (API) till the situation improves.”

Seven Indian companies are producing injection remdesivir under voluntary licensing agreement with Gilead Sciences, US. They have an installed capacity of about 38.80 lakh units per month.

In addition, the Central government has taken several steps to ensure easy access of hospital and patients to remdesivir.

As part of its effort, it has advised all domestic manufactures of remdesivir to display details of their stockists or distributors on their websites to facilitate access to the drug.
ADVERTISEMENT

"Drugs inspectors and other officers have been directed to verify stocks and check malpractices and also take other effective actions to curb hoarding and black marketing," the Ministry said.

"The state Health Secretaries will review this with the Drug Inspectors of the respective states and Union Territories (UTs). The Department of Pharmaceuticals has been in contact with the domestic manufacturers to ramp up the production of Remdesivir."

The Centre has also advised states that the "National Clinical Management Protocol for Covid-19", developed after many interactions by Committee of Experts, is the guiding document for treatment of Covid-19 patients and lists remdesivir as an investigational therapy, where informed and shared decision making is essential, besides taking note of contra indications mentioned in the detailed guidelines.

The states and UTs have been advised that these steps should again be communicated to all hospitals, both in public and private sector, and compliance monitored.

(This story was published from a syndicated feed. Only the headline and picture has been edited by FIT).

(This story was auto-published from a syndicated feed. No part of the story has been edited by The Quint.)

(The Quint is available on Telegram. For handpicked stories every day, subscribe to us on Telegram)

We'll get through this! Meanwhile, here's all you need to know about the Coronavirus outbreak to keep yourself safe, informed, and updated.

Liked this story? We'll send you more. Subscribe to The Quint's newsletter and get selected stories delivered to your inbox every day. Click to get started.

The Quint is available on Telegram & WhatsApp too, click to join.

Read and Breaking News at the Quint, browse for more from fit and coronavirus

Topics:  coronavirus   Corona   covid 19 

Speaking truth to power requires allies like you.
Become a Quint Insider
25
100
200

or more

PREMIUM

3 months
12 months
12 months
Check Insider Benefits
ADVERTISEMENT
Stay Updated

Subscribe To Our Daily Newsletter And Get News Delivered Straight To Your Inbox.

Join over 120,000 subscribers!
ADVERTISEMENT
×
×